Chiome Bioscience Inc. (4583) AI Stock Analysis

• Market Cap: ¥9.53B
• Dividend Yield: N/A
• Average Volume (3M): 831.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 30.92%
• EPS Growth: 26.00%
• Country: JP
• Employees: 47
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -3.94
• Shares Outstanding: 68,053,800
• 10 Day Avg. Volume: 852,210
• 30 Day Avg. Volume: 831,223
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ―

Chiome Bioscience Inc.'s overall stock score reflects its mixed financial performance, where revenue growth is offset by lack of profitability and negative cash flow. The stock's technical indicators are weak, and the negative P/E ratio makes it less attractive in terms of valuation. The company needs to focus on achieving profitability and improving cash flows to strengthen its financial standing.

Chiome Bioscience Inc. Business Overview & Revenue Model

Company Description

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer which is under phase 1 trial; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma which is under phase 1 trial; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and breast cancer (TNBC) which is under phase 1 trial. The company's product pipeline under preclinical study includes LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases; PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, triple negative breast cancer; and PFKR, anti-CX3CR1 antibody for secondary progressive multiple sclerosis. It serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Chiome Bioscience Inc. generates revenue primarily through the development and commercialization of its therapeutic antibody candidates. The company earns money by licensing its proprietary ADLib system technology to other pharmaceutical companies, enabling them to discover and develop their own antibody products. Additionally, Chiome may receive milestone payments and royalties from partnerships and collaborations with other biotech and pharmaceutical firms. These partnerships often involve co-development agreements where Chiome contributes its expertise in antibody research and development. The company's revenue model is also supported by potential government grants and funding for its research endeavors.

Chiome Bioscience Inc. Financial Statement Overview

Summary

Chiome Bioscience Inc. shows revenue growth but struggles with profitability due to persistent negative net income and EBIT. The company has a strong equity position and low leverage but faces challenges with cash flow, indicating a need for improved operational efficiencies.

Income Statement

Chiome Bioscience Inc. shows a consistent increase in total revenue over recent years, with a noticeable revenue growth rate of 14.41% from 2023 to 2024. However, the company suffers from persistently negative net income and EBIT, leading to negative net profit margins and EBIT margins. This suggests the company is struggling to convert revenue into profit, a pressing concern for financial health.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 77.81% in 2024, indicating a solid foundation of stockholders' equity relative to total assets. The debt-to-equity ratio remains low at 0.15, highlighting minimal leverage risk. However, persistent losses and continued reliance on equity financing could pose future sustainability challenges.

Cash Flow

Chiome Bioscience Inc. exhibits stable operational cash outflows, with operating cash flow improving slightly from 2023 to 2024. However, the free cash flow remains negative, and the free cash flow to net income ratio indicates operational inefficiencies. These aspects highlight challenges in achieving positive cash flow without external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	780.81M	682.46M	630.82M	712.93M	480.85M
Gross Profit	432.85M	398.60M	348.86M	422.46M	245.27M
EBITDA	-1.01B	-1.21B	-1.24B	-1.46B	-1.29B
Net Income	-1.02B	-1.22B	-1.24B	-1.48B	-1.29B
Balance Sheet
Total Assets	2.47B	1.75B	2.22B	2.34B	3.49B
Cash, Cash Equivalents and Short-Term Investments	2.06B	1.33B	1.73B	1.79B	2.69B
Total Debt	281.50M	291.00M	184.00M	183.00M	180.00M
Total Liabilities	548.55M	593.73M	424.72M	446.39M	384.59M
Stockholders Equity	1.92B	1.16B	1.79B	1.89B	3.11B
Cash Flow
Free Cash Flow	-1.00B	-1.07B	-1.19B	-1.13B	-1.36B
Operating Cash Flow	-1.00B	-1.07B	-1.19B	-1.13B	-1.36B
Investing Cash Flow	0.00	173.00K	0.00	-35.38M	-3.52M
Financing Cash Flow	1.74B	667.30M	1.13B	271.35M	1.94B

Chiome Bioscience Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 141.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Negative. The current price of 141 is below the 20-day moving average (MA) of 144.50, below the 50-day MA of 147.96, and below the 200-day MA of 166.78, indicating a bearish trend. The MACD of -2.33 indicates Positive momentum. The RSI at 41.47 is Neutral, neither overbought nor oversold. The STOCH value of 30.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4583.

Chiome Bioscience Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2370	59 Neutral	¥10.06B	―		―	-0.97%	1.19%
4584	55 Neutral	¥15.75B	46.96		―	120.34%	―
Sector *	51 Neutral	$7.71B	-0.22	-44.71%	2.25%	22.42%	-0.92%
4583	48 Neutral	¥9.53B	―		―	30.92%	26.00%
3NQ	―	€64.42M	―	-31.29%	―	―	―
4588	44 Neutral	¥18.10B	―		―	-9.04%	2.12%
4893	41 Neutral	¥7.62B	―		―	-96.99%	29.33%

Chiome Bioscience Inc. Corporate Events

Chiome Bioscience Updates Financial Results for FY 2024

Chiome Bioscience Inc. has issued corrections to its previously released non-consolidated financial results for the fiscal year ended December 31, 2024. The corrections pertain to minor adjustments in cash flows from operating and financing activities, as well as details in the cost of sales. These adjustments reflect slight changes in financial figures, which may have implications for stakeholders analyzing the company’s financial health and operational efficiency.

Chiome Bioscience and OmniAb Collaborate on Antibody Research

Chiome Bioscience Inc. has entered a collaborative research agreement with OmniAb, Inc. to explore synergies in bispecific antibody generation. This partnership aims to implement a high throughput screening system, leveraging OmniAb’s OmniClic platform, to enhance Chiome’s antibody development capabilities and strengthen its profitability. The financial impact for the fiscal year ending December 2025 is expected to be minimal.

Chiome Bioscience Reports Modest Sales Growth Amid Continued Financial Challenges

Chiome Bioscience Inc. reported a modest increase in net sales for the fiscal year 2024, reaching 780 million yen, reflecting a 14.4% rise from the previous year. Despite this growth, the company continues to face financial challenges with significant losses in operating and net income, indicating ongoing struggles within its operations. The financial position improved with an increase in total assets and net assets, showcasing a strengthened equity ratio. The company is cautious about its future financial results, particularly in the drug discovery and development sector, and has only provided forecasts for the drug discovery support business.

Chiome Bioscience’s Tribody™ Technology Shows Promising Results in Cancer Immunotherapy

Chiome Bioscience Inc. announced the publication of a research paper in collaboration with Ceinge-Biotecnologie Avanzate, highlighting the effectiveness of their Tribody™ technology in cancer immunotherapy. The study demonstrated that their tri-specific Tribody™ antibody could enhance T cell responses more effectively than existing combination therapies by targeting tumor-associated antigens and immune checkpoint molecules. This advancement suggests significant potential for the Tribody™ technology to improve cancer treatment efficacy, potentially impacting the broader biotech and pharmaceutical sectors by reducing the complexity of cancer therapies for patients.